microtiter plate elisa reads fluostar optima (BMG Labtech)
Structured Review

Microtiter Plate Elisa Reads Fluostar Optima, supplied by BMG Labtech, used in various techniques. Bioz Stars score: 99/100, based on 20361 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/microtiter+plate+elisa+reads+fluostar+optima/FLUOstar+Omega/bio_rxiv__64898__2026__03__26__714543-98-21-27
Average 99 stars, based on 20361 article reviews
Images
1) Product Images from "Pharmacodynamic and stage-dependent therapeutic efficacy of SFRP1 neutralization in a mouse model of Alzheimer’s disease"
Article Title: Pharmacodynamic and stage-dependent therapeutic efficacy of SFRP1 neutralization in a mouse model of Alzheimer’s disease
Journal: bioRxiv
doi: 10.64898/2026.03.26.714543
Figure Legend Snippet: ELISA quantification of biotinylated α-SFRP1 mAb levels in (A) serum and (B) brain RIPA-soluble homogenates from 4-8 month-old APP/PS1 mice. Samples were collected 6 and 24 h after a single 100 µg intraperitoneal or retro-orbital injection of α-SFRP1. “Pre-Inj.” Indicates mAb levels before the injection (expected to be zero). Data are presented as mean ± SEM. Statistical analyses were performed using (A) two-way ANOVA followed by Sidak’s post hoc test for multiple comparisons or (B) Mann-Whitney test.
Techniques Used: Enzyme-linked Immunosorbent Assay, Injection, MANN-WHITNEY
Figure Legend Snippet: ( A ) Schematic of the experimental design. 4-month-old homozygous APP/PS1 mice received weekly retro-orbital injections of IgG1 or α-SFRP1.10 (100 µg) for 5 months; analyses in panels ( B–G ) were performed at 9 months of age. The time diagram indicates the expected age at which these mice initiate amyloid-β plaque accumulation. Illustration from NIAID NIH BioArt Source ( https://bioart.niaid.nih.gov/ ). ( B ) ELISA quantification of SFRP1 levels in brain RIPA-soluble homogenates. ( C ) Representative confocal images of cortices (top) and hippocampi (bottom) from IgG1-treated (left) and α-SFRP1.10-treated (right) mice stained with Thioflavin S (ThioS) to label amyloid plaque cores. Scale bar: 100 µm. Quantification of the number (top) and mean plaque area (bottom) of ( D ) ThioS+ plaques and ( E ) LAMP1-positive puncta in the cortex (left) and hippocampus (right). Quantification of (F) GFAP and (G) Iba1 fluorescence intensity in the cortex (left) and hippocampus (right), expressed as fold change relative to the mean value of the IgG1 group. Quantification analyses were performed for individual mice, averaging the results of 3-8 slices per mouse. Data are presented as mean ± SEM. Statistical analyses were performed using Student’s t test.
Techniques Used: Enzyme-linked Immunosorbent Assay, Staining, Fluorescence
Figure Legend Snippet: ( A ) Schematic of the experimental design. 4-month-old homozygous APP/PS1 mice received weekly retro-orbital injections of IgG1 or α-SFRP1.10 (200 µg) for 2 months; analyses in panels ( B–H ) were performed at 6 months of age. The time diagram indicates the expected age at which these mice initiate amyloid-β plaque accumulation. Illustration from NIAID NIH BioArt Source ( https://bioart.niaid.nih.gov/ ). ( B ) Kaplan–Meier curves showing mouse survival during the treatment period; each vertical step represents a death event. ( C ) ELISA quantification of SFRP1 levels in brain RIPA-soluble homogenates. ( D ) Representative confocal images of cortices (top) and hippocampi (bottom) from IgG1-treated (left) and α-SFRP1.10-treated (right) mice stained with Thioflavin S (ThioS) to label amyloid plaque cores. Scale bar: 100 µm. Quantification of the number (top) and mean plaque area (bottom) of ( E ) ThioS+ plaques and ( F ) LAMP1+ puncta in the cortex (left) and hippocampus (right). Quantification of (G) GFAP and (H) Iba1 fluorescence intensity in the cortex (left) and hippocampus (right), expressed as fold change relative to the mean value of the IgG1 group. Quantification analyses were performed for individual mice, averaging the results of 3-8 slices per mouse. Data are presented as mean ± SEM. Statistical analyses were performed using Student’s t test.
Techniques Used: Enzyme-linked Immunosorbent Assay, Staining, Fluorescence
Figure Legend Snippet: ( A ) Schematic of the experimental design. 8-month-old heterozygous APP/PS1 mice received weekly retro-orbital injections of WAY-316606 (1 µM) or vehicle (2% DMSO) for 2 months; analyses in panels ( B–D ) were performed at 10 months of age. The time diagram indicates the expected age at which these mice initiate amyloid-β plaque accumulation. Illustration from NIAID NIH BioArt Source ( https://bioart.niaid.nih.gov/ ). ( B ) ELISA quantification of SFRP1 levels in brain RIPA-soluble homogenates. ( C ) Representative confocal images of cortices (top) and hippocampi (bottom) from vehicle-treated (left), WAY-316606-treated (center) mice stained with ThioS to label amyloid plaque cores. Scale bar: 100 µm. Quantification of number (top) and mean plaque area (bottom) of ( D ) ThioS+ plaque and LAMP1+ puncta ( E ) in the cortex (left) and hippocampus (right). Quantification analyses were performed for individual mice, averaging the results of 3-8 slices per mouse. Data are presented as mean ± SEM. Statistical analyses were performed using Student’s t test.
Techniques Used: Enzyme-linked Immunosorbent Assay, Staining
Related Articles
Enzyme-linked Immunosorbent Assay:Article Title: Pharmacodynamic and stage-dependent therapeutic efficacy of SFRP1 neutralization in a mouse model of Alzheimer’s disease Article Snippet: After extensive washing with PBST, the enzymatic reaction was developed at RT in the dark for 20 min using tetra-methyl-benzidine liquid substrate (100 μl/well; Sigma-Aldrich, USA). .. The reaction was terminated by adding 2N HCl (100 μl/well), and the resulting product was measured at 450 nm in a |